DeepX Diagnostics announced that its novel digital dermatoscope, DermoSight, has received clearance from the U.S. Food and Drug Administration (FDA) for use during teledermatology screenings of potentially cancerous skin lesions. The digital dermatoscope was designed for integration with an artificial intelligence algorithm supported by optical transfer diagnosis—a technology capable of providing an assessment of deep layers of high-risk skin lesions under the skin through optical analysis. However, the optimal transfer diagnosis technology has not yet been approved for commercial use with DermoSight by the FDA. “DermoSight is only the first step in our vision to make skin cancer diagnosis directly accessible in primary care and beyond, and to reduce referrals and waiting times,” concluded Hans Gangeskar, Chief Executive Officer of Overture Life and a board member at DeepX Diagnostics.
June 22, 2023